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Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented
adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary
macroadenoma who underwent transsphenoidal surgery. The patient’s condition improved but GH and IGF-I levels did not
normalize; as a consequence, we first administered dopamine agonists and then somatostatin receptor ligands (SRLs) with poor
response. PEGv 15mg every other day was added to lanreotide 120mg monthly. The patient developed a severe hepatitis five
months after starting the combination therapy. Elevated ferritin, iron, and transferrin saturation suggested probable hepatitis due
to haemochromatosis. We performed a liver biopsy which showed an acute cholestatic hepatitis consistent with toxic etiology. A
heterozygous genotype UGT1A1∗28 polymorphism associated with Gilbert’s syndrome was also found in this Argentine patient.
The predominant clinical presentation resembled an acute cholestatic hepatitis associated with severe hemosiderosis, a different
and new pattern of PEGv hepatotoxicity.
1. Introduction
Acromegaly is a rare disease usually derived from a GH-
secreting pituitary tumor.
The increased mortality among persons with acromegaly
includes higher prevalence of hypertension, hyperglycemia or
overt diabetes, cardiomyopathy, and sleep apnea [1].
Currently, surgery is the primary approach for treating
most patients. If cure is not achieved with this treatment,
pharmacotherapy should be considered. Somatostatin recep-
tor ligands (SRLs) are usually the first line therapy for
treating active acromegaly. Pegvisomant (PEGv), a pegylated
GH receptor antagonist, is another effective therapeutic
option that could be administered alone or in combination
with SRLs [2–4]. PEGv is usually well-tolerated; however, it
might cause adverse events such as drug-induced liver injury
[3].
Bernabeu et al. found that the UGT1A1∗28 genotype
associated with Gilbert’s syndrome predicts an increased
incidence of liver abnormalities during PEGv therapy in
Spanish acromegalic patients [4].
We report here clinical, biochemical, genotype, and his-
tological findings in an Argentine acromegalic patient who
developed a severe cholestatic hepatitis during PEGv therapy.
2. Case Report
In 1996 a 39-year-old man was referred to the Endocrinology
Service of the Hospital Militar Central of Buenos Aires City
because he presented arterial hypertension and acromegalic
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Table 1: Chronological development and values of alkaline phosphatase (APh), 𝛾-glutamyltranspeptidase (GGT), total bilirubin (T. Bil),
ferritin, transferrin saturation (TSAT), and iron during the combination therapy with PEGv and after stopping this treatment.
During combination therapy After stopping combination therapy
2 Months 5 Months 10 Days 1 Month 2 Months 3 Months 4 Months
APh (40–120UI/L) 136 272 242 99 99 92 80
GGT (8–61UI/L) 549 166 166 77 17
T. Bil (0.1–1mg/dL) 0.4 2.5 1.9 0.64 0.64 0.61 0.61
Ferritin (30–400 ng/mL) 4836 763 595 374 191
Transferrin (200–360 ug/dL) 212 198 194 210 244
TSAT (15–50%) 104 72 50
Iron (59–158 ug/dL) 180 180 154
features. He had a two-year history of headaches, sweating,
feet and hands enlargement, weight gain, erectile dysfunc-
tion, and hyperglycemia. His lab tests showed an elevated
IGF-I level: >5.4U/mL (NR: 0.6–5.4) and nonsuppressible
GH postoral glucose tolerance test (OGTT) (GH nadir:
78 ng/mL). He underwent a magnetic resonance imaging
(MRI) which showed a pituitary macroadenoma of 18 ×
15mm with suprasellar extension. The patient was oper-
ated on by transsphenoidal approach. The pathology report
informed a diffuse eosinophilic pituitary adenoma. At that
time we could not perform immunochemistry.
The symptoms and hormonal test improved; however,
GH and IGF-I levels were persistently elevated.
In December 1996 bromocriptine 3.75mg/day was indi-
cated without normalization of IGF-I. Two years later, he
was medicated with cabergoline 0.5mg/week with poor tol-
erance and response; therefore, he returned to bromocriptine
5mg/day. He stopped treatment and was lost to follow-up
for five years. When the patient returned in 2003, an MRI
showed no tumor but his IGF-I level was elevated; therefore,
cabergoline was indicated. He was not consistent with the
treatment because he presented poor tolerance to this drug.
In 2005 he was started on octreotide 30mg/month with
partial response.
Due to severe coronary heart disease, inOctober 2007 the
patient underwent a coronary bypass surgery. In December
2008, as he presented glucose intolerance, amore sensible diet
and metformin (1,700mg/day) were indicated.
In 2010 a cholecystectomy was performed because of the
development of gallstones. In 2011 two benign polyps and a
villous adenoma were removed during a colonoscopy.
In 2012 octreotide was switched to lanreotide 120mg/
month. Because of increased IGF-I levels, in March 2013
PEGv 15mg every other day was added. Up to that moment
the patient’s liver function tests had always been normal.
It is important to note that he did not drink alcohol. He
was also medicated with atenolol 25mg/day and enalapril
10mg/day and continued metformin treatment. In May
2013 he presented transient symptoms of flu and a slight
increase of transaminases, less than 3 times above the upper
limit of normal (×ULN). In August 2013 the patient, under
treatment with lanreotide and PEGv, had a normal IGF-I
level, 154 ng/mL (81–225), but he unexpectedly experienced
abdominal pain, severe asthenia, decreased appetite, and

















































Figure 1: Chronological development of ASAT and ALT transami-
nases during the combination therapy with PEGv and after stopping
this treatment.
Liver tests results showed elevated levels of aspartate amino-
transferase (ASAT) 29.9 ×ULN, alanine aminotransferase
(ALT) 45.3 ×ULN, alkaline phosphatase (APh) 2.26 ×ULN,
and total bilirubin 2.5 ×ULN. Prothrombin time (PT) and
activated partial thromboplastin time (aPTT) were both
normal (PT: 85% (70–120) and aPTT: 39 seconds (27–42)).
Blood cell count was normal: hematocrit 45%, hemoglobin:
15 grams/dL, and white blood cell count: 7100 cells/mcL with
no eosinophilia.There were no changes in the normal pattern
of coagulation tests and blood cell count during the course
of the hepatic disease. The tests for viral and autoimmune
hepatitis were negative. Elevated ferritin, iron, and transfer-
ring saturation (TSAT) suggested probable hepatitis due to
haemochromatosis. Liver and iron tests are shown in Table 1
and in Figure 1.The abdominal ultrasonography was normal.
We decided to stop treatment with both lanreotide and PEGv.
Case Reports in Endocrinology 3
(a) (b)
Figure 2: (a and b) Bridging periportal collapse with a mild number of inflammatory cells, HE, and Masson’s trichrome, 100x, respectively.
See arrows.
We performed a liver biopsy which showed an acute
cholestatic hepatitis with confluent necrosis, which formed
portocentral bridges of parenchymal collapse (Figures 2(a)
and 2(b)). There were deposits of iron predominantly in
reticuloendothelial cells, a patternwhich does not correspond
to genetic haemochromatosis (Figure 3). Inflammatory cells
included eosinophils (Figure 4). These findings were consis-
tent with a severe acute hepatitis of toxic etiology.
Haemochromatosis was also ruled out through a negative
result of C282Y and H63D genotypes of haemochromatosis
HFE.
The genotype UGT1A1∗28 associated with Gilbert’s
syndrome was performed and a heterozygous genotype
UGT1A1∗28 polymorphism was found. The UGT1A1∗28
genotyping was performed by PCR amplification of a
fragment of the UGT1A1 gene promoter, which included
the TATA box, and Sanger sequencing of the amplification
product.
Liver function tests returned to normal four months after
PEGv discontinuation and they have been normal since then.
Without combination therapy, IGF-I levels increased
to 367 ng/mL (NR: 81–225) (1.63 ×ULN). In January 2014
lanreotide 120mg monthly and cabergoline 0.5mg/week
were indicated with good tolerance and thus IGF-I levels
normalized: 205 ng/mL.
3. Discussion
The association of PEGv therapy with drug-induced hep-
atic events is well-documented; however, the mechanisms
responsible for its toxicity remain unclear [3].
In the German Pegvisomant Observational Study, PEGv
administration was associated with an increase in liver
enzymes in 9% of patients [5]. ACROSTUDY reported that
30 (2.5%) of 1178 patients had elevated aspartate amino-
transferase or alanine aminotransferase greater than three
times the upper level of normal during PEGv therapy; a
spontaneous recovery of transaminases frequently occurred
despite continuation of PEGv [6].
According to Bernabeu et al., the UGT1A1∗28 genotype
associatedwithGilbert’s syndromepredicts an increased inci-
dence of liver abnormalities during PEGv therapy in Spanish
Figure 3: Moderate hemosiderosis: iron stores in reticuloendothe-
lial cells, Perls stain, 400x. See arrows.
Figure 4: Focal acinar collapse. Sinusoidal inflammatory foci with
some eosinophils. Hepatocyte cytoplasmic cholestasis, HE, 400x.
See arrows.
patients. The excretion pathways of PEGv are unknown; in
humans <0.6% of unchanged PEGv is excreted in urine.
Nothing is known about the hepaticmetabolism of PEGv and
whether it requiresUGT1A1-mediated glucuronidation [4, 5].
Although our patient had never shown increased bilirubin in
order for us to be able to diagnose Gilbert’s syndrome, we
found a heterozygous genotype UGT1A1∗28 [7].
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Drug-induced hepatotoxicity is a frequent cause of liver
disease and canmimic all forms of acute and chronic hepato-
biliary diseases. Based on ALT and APh levels, drug-induced
liver injury is classified into acute hepatitis, cholestasis, or
mixed patterns. This classification was established by the
Council for International Organization of Medical Sciences
and modified by US FDA Drug Hepatotoxicity Steering
Committee [8]. Establishing its diagnosis requires exclusion
of other causes of liver injury.
The liver is the central organ responsible for the selective
uptake, metabolism, and excretion of drugs, xenobiotics, and
environmental toxins.This essential function predisposes the
liver to drug toxicity [9].
Adverse hepatic events caused by drugs can be con-
sidered to be either predictable (high incidence) or unpre-
dictable (low incidence). The most common example of a
drug causing predictable drug-induced liver injury (DILI) is
acetaminophen. This type of drug injury has a short latency
period, is dose-related, and is the most common form of
DILI. On the contrary, idiosyncratic DILI is unpredictable,
has longer/variable latency, and is less common [10].
The pathogenesis of drug-induced liver injury usually
involves the participation of a toxic drug or a metabolite
that either elicits an immune response or directly affects the
biochemistry of the cell. Most adverse drug-induced hepatic
events are unpredictable and are either immune-mediated
hypersensitivity reactions or idiosyncratic ones [11].
The liver removes lipophilic chemicals from blood,
including drugs, and biotransforms them into water-soluble
metabolites which are excreted. This process involves
cytochrome P450 (phase 1), conjugation (phase 2), and
transport (phase 3). The expression of the enzymes and
transporters involved in the hepatic handling of drugs are
under the control of transcriptions factors (nuclear hormone
receptors). In humans, polymorphisms of the genes that
regulate each phase and transcription factors affect their
activities and expression in response to environmental
factors. So it is likely that the level of exposure to the toxic
moiety (reactive metabolite or the parent drug) is the most
upstream determinant of DILI [12].
Acromegaly by itself is correlated with a high prevalence
of gallbladder stones and the long-term treatment with SRLs
increases the incidence of cholelithiasis [13]. Our patient
underwent a cholecystectomy, probably related to octreotide
treatment. Five years later, at the onset of symptoms of
hepatitis, his abdominal ultrasound was normal; that is why
liver or biliary diseases were excluded.
Laboratory tests showed elevated ferritin and transferrin
saturation suggesting probable hepatitis due to haemochro-
matosis, which was ruled out through a negative of C282Y
and H63D genotypes and the liver biopsy. It is known that
both ferritin and TSAT can also be elevated in many inflam-
matory conditions such as viral hepatitis, regular alcohol
consumption, and fatty liver disease [14].
Filopanti et al. showed that in acromegalic patients
treated with PEGv, multitherapies and previous episodes of
liver disease were associated with increased risk of hepato-
toxicity; however, they did not find any increased risk of liver
toxicity in Italian patients with UGT1A1∗28 polymorphism
[15]. Our patient was not medicated with any other probable
hepatotoxic drug.
Neggers et al. found only 13.5% of transiently elevated
liver transaminases (TET) above 3 ×ULN, of which 83%
occurred within the first year of combination treatment with
somatostatin analogs and PEGv. In their study, they detected
the UGT1A1∗28 polymorphism in 54.2% of their patients;
however, they could not confirm any association between
this polymorphism and TET [16]. Our patient presented a
slight increase of transaminases twomonths after starting the
combination therapy and developed a severe hepatitis five
months afterwards.
The presence of the UGT1A1∗28 genotype in our Argen-
tine patient might be related to his Spanish ancestry (he had
three Spanish grandparents). This finding is in accordance
with Bernabeu et al. study in Spanish acromegalic population.
Besides there is another coincidence with their study: our
patient is male [4].
The mechanism of pegvisomant-induced liver injury
remains the subject of conjecture. We report a patient with
acromegaly who developed a severe drug-induced hepatitis
during treatment with PEGv. When PEGv was discontinued,
his laboratory tests normalized in four months.
Although in this case we might assume that it was an
idiosyncratic drug toxicity, to the best of our knowledge,
it is the first case described in which its predominant
clinical presentation resembles an acute cholestatic hepatitis
associated with severe hemosiderosis, a different pattern of
PEGv hepatotoxicity.
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